Navigation Links
BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference
Date:1/8/2009

nd other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current phar
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Spartan Bioscience announced today that Health Canada ... It detects CYP2C19 genetic mutations in less than 60 ... RX CYP2C19 System is the first near-patient DNA test ... Due to the system’s ease of use, Health Canada ... professionals such as doctors, nurses, pharmacists, and laboratory technicians, ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success ... of its fleet of high volume High Pressure Processing (HPP) ... we return to PackExpo this year, which is where we ... said Jeff Williams, CEO at Avure. “Sales of the new ... be meeting the challenges of market demand for higher throughput. ...
(Date:10/30/2014)... CARLSBAD, Calif. , Oct. 30, 2014 Isis ... antisense therapeutics, today announced that management will present a company ... 2014 at 8:30 a.m. ET in Boston, MA. ... will be available on the "Investors & Media" section of ... available on the Isis website within 48 hours and will ...
(Date:10/30/2014)... 2014  Regado Biosciences, Inc. (Nasdaq: RGDO ... call and live audio webcast on Thursday, November 6, ... quarter 2014 financial results. Interested participants and ... 347-1165 for domestic callers or (412) 902-4276 for international ... the investor relations section of the Regado website at ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2
... news item is out of step with public opinion in ... state of Wisconsin grants $1 million and loans another $1 ... UW-Madison researcher so renowned that the words "Nobel Prize" practically ... drug discovery. , ,• The National Institutes of Health, the ...
... records have led to some adoption of the technology but ... ,Then Hurricane Katrina slammed into the Gulf Coast, destroying countless ... ,Katrina, and her followup Rita, may not only have changed ... focus of debate on electronic healthcare records. It is becoming ...
... -- Research scientist Seth Dobrin, Ph.D., has been named ... Genotyping Service of the Marshfield Clinic Research Foundation. , ,He ... to problems of mental health and development of new genetic ... discoveries he made earlier in his career as well as ...
Cached Biology Technology:Stem cell bank announcement validates quality of Wisconsin research 2Stem cell bank announcement validates quality of Wisconsin research 3Katrina's destruction likely to speed up electronic healthcare records adoption 2Katrina's destruction likely to speed up electronic healthcare records adoption 3Katrina's destruction likely to speed up electronic healthcare records adoption 4
(Date:10/28/2014)... differences in moving activity in a novel environment ... angling, according to an experimental study completed at ... Game and Fisheries Research Institute. The study used ... and authentic angling trials to analyse if behaviours ... reared in traditional and enriched hatchery rearing environments. ...
(Date:10/28/2014)... and citrus fruits and juices are associated with a ... research from the University of East Anglia (UEA). ... foods containing flavonols and flavanones (both subclasses of dietary ... cancer, the fifth-leading cause of cancer death among women. ... of 171,940 women aged between 25 and 55 for ...
(Date:10/27/2014)... are an indigenous species of the West Antarctic Peninsula ... Earth. Since 1950, the average annual temperature in the ... and 6 degrees Celsius during winter. , As ... dry, polar system to a warmer, sub-polar system with ... a connection between local weather conditions and the weight ...
Breaking Biology News(10 mins):Fish 'personality' linked to vulnerability to angling 2Tea and citrus products could lower ovarian cancer risk, new UEA research finds 2University of Delaware study connects penguin chick weights to local weather conditions 2University of Delaware study connects penguin chick weights to local weather conditions 3
... they used fluorescent molecules to "tag" DNA and monitor a ... rearranging genetic material in some types of cells. ... light on how DNA loops form, but also might be ... shuffle genetic material, such as HIV. Until now, scientists ...
... more DNA regions linked to type 2 diabetes have been ... to over 60. The study provides a fuller picture ... with some clear patterns emerging. The international team, ... Institute of Harvard and MIT, and the University of Michigan, ...
... affordable and accessible, we need to pay more attention to ... and the fact that we don,t yet understand what ... Hastings Center Report . The authors are current or former ... Most analyses of the ethical issues raised by whole ...
Cached Biology News:Scientists use light to 'tag and track' genetic processes 210 new diabetes gene links offer picture of biology underlying disease 210 new diabetes gene links offer picture of biology underlying disease 3Prenatal whole genome sequencing: Just because we can, should we? 2Prenatal whole genome sequencing: Just because we can, should we? 3
... MAX POWER 500V Programmable Power Supply ... which can handle virtually any application ... current blotting. It is unique in ... The MAX POWER Programmable Power Supply ...
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
...
BD BioCoat Laminin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
Biology Products: